181 related articles for article (PubMed ID: 17267584)
1. Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor-beta/activin receptor-like kinase-4/5/7/Smad2 signaling pathway.
Ruiz E; Redondo S; Gordillo-Moscoso A; Tejerina T
J Pharmacol Exp Ther; 2007 May; 321(2):431-8. PubMed ID: 17267584
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism.
Redondo S; Ruiz E; Santos-Gallego CG; Padilla E; Tejerina T
Diabetes; 2005 Mar; 54(3):811-7. PubMed ID: 15734860
[TBL] [Abstract][Full Text] [Related]
3. Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism.
Jeon ES; Moon HJ; Lee MJ; Song HY; Kim YM; Bae YC; Jung JS; Kim JH
J Cell Sci; 2006 Dec; 119(Pt 23):4994-5005. PubMed ID: 17105765
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone inhibits homocysteine-induced migration of vascular smooth muscle cells through a peroxisome proliferator-activated receptor gamma-independent mechanism.
Li L; Gao PJ; Xi R; Wu CF; Zhu DL; Yan J; Lu GP
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1471-6. PubMed ID: 18759864
[TBL] [Abstract][Full Text] [Related]
5. IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells.
Kuemmerle JF; Murthy KS; Bowers JG
Am J Physiol Gastrointest Liver Physiol; 2004 Oct; 287(4):G795-802. PubMed ID: 15178549
[TBL] [Abstract][Full Text] [Related]
6. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation.
Giordano A; Romano S; Mallardo M; D'Angelillo A; Calì G; Corcione N; Ferraro P; Romano MF
Cardiovasc Res; 2008 Aug; 79(3):519-26. PubMed ID: 18349138
[TBL] [Abstract][Full Text] [Related]
7. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells.
Herrmann J; Borkham-Kamphorst E; Haas U; Van de Leur E; Fraga MF; Esteller M; Gressner AM; Weiskirchen R
Biochem Biophys Res Commun; 2006 Jul; 345(4):1526-35. PubMed ID: 16735029
[TBL] [Abstract][Full Text] [Related]
8. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
9. Role of TGF-beta1 in vascular smooth muscle cell apoptosis induced by angiotensin II.
Redondo S; Ruiz E; Padilla E; Gordillo-Moscoso A; Tejerina T
Eur J Pharmacol; 2007 Feb; 556(1-3):36-44. PubMed ID: 17169354
[TBL] [Abstract][Full Text] [Related]
10. [Interaction between TGF-beta1/Smad pathway and ERK pathway in vascular smooth muscle cells].
Zhong H; He F; Hu QH; Wang ZH; Deng FM; Sun ZP; Li ZC
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2010 Feb; 26(1):15-8. PubMed ID: 20476555
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models.
Gu J; Liu X; Wang QX; Guo M; Liu F; Song ZP; Zhang DD
J Mol Cell Cardiol; 2013 Dec; 65():1-8. PubMed ID: 24100253
[TBL] [Abstract][Full Text] [Related]
12. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
13. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II-induced differentiation of adipose tissue-derived mesenchymal stem cells to smooth muscle-like cells.
Kim YM; Jeon ES; Kim MR; Jho SK; Ryu SW; Kim JH
Int J Biochem Cell Biol; 2008; 40(11):2482-91. PubMed ID: 18571460
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2.
Wakino S; Hayashi K; Kanda T; Tatematsu S; Homma K; Yoshioka K; Takamatsu I; Saruta T
Circ Res; 2004 Sep; 95(5):e45-55. PubMed ID: 15308580
[TBL] [Abstract][Full Text] [Related]
17. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
19. Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β.
Groenendijk BC; Benus GF; Klous A; Pacheco YM; Volger OL; Fledderus JO; Ferreira V; Engelse MA; Pannekoek H; ten Dijke P; Horrevoets AJ; de Vries CJ
Exp Cell Res; 2011 Jan; 317(2):131-42. PubMed ID: 20955695
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-β are prevented by PPAR-γ agonists.
Hatanaka H; Koizumi N; Okumura N; Kay EP; Mizuhara E; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6955-63. PubMed ID: 22956604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
